In Vitro Antiviral Activity of Cabotegravir against HIV-2.

ABSTRACT: We examined the antiviral activity of the integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naive individuals. HIV-2 was sensitive to cabotegravir in single-cycle and spreading-infection assays, with 50% effective concentrations (EC₅₀s) in the low to subnanomolar range; comparable results were obtained for HIV-1 in both assay formats. Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings.

SUBMITTER: Smith RA 

PROVIDER: S-EPMC6153831 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature